DCM Shriram's Executive Director Dr. Paresh Verma Set to Retire After 23-Year Tenure
DCM Shriram Consolidated announced the retirement of Dr. Paresh Verma, Executive Director and Research Director for the Bioseed Research Business, effective October 31, 2025. Dr. Verma has served the company for over 23 years and will cease to be a Senior Management Personnel upon retirement. The company has informed stock exchanges in compliance with SEBI regulations.

*this image is generated using AI for illustrative purposes only.
DCM Shriram Consolidated , a prominent player in the Indian agri-rural business sector, has announced a significant change in its senior management. Dr. Paresh Verma, the company's Executive Director and Research Director for the Bioseed Research Business, is slated to retire after more than two decades of service.
Key Details of the Retirement
| Aspect | Details |
|---|---|
| Retiring Executive | Dr. Paresh Verma |
| Current Position | Executive Director & Research Director - Bioseed Research Business |
| Effective Date | October 31, 2025 (closing of business hours) |
| Tenure | Over 23 years |
Impact on Company Structure
The retirement of Dr. Verma marks the end of an era for DCM Shriram's Bioseed Research Business. As per the company's announcement, Dr. Verma will cease to be a Senior Management Personnel (SMP) upon his retirement. This change comes as part of the natural progression of leadership within the organization.
Company's Response
DCM Shriram's management has expressed its gratitude for Dr. Verma's long association with the company. The announcement, made in compliance with SEBI regulations, highlights the significant role Dr. Verma has played in leading the Bioseed Research Business for more than two decades.
Regulatory Compliance
The company has duly informed the stock exchanges about this development, adhering to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As the change in Senior Management Personnel is due to retirement, the company noted that a resignation letter is not applicable in this case.
Looking Ahead
While the company has not yet announced a successor for Dr. Verma's position, this transition presents an opportunity for DCM Shriram to potentially bring in new perspectives to its Bioseed Research Business. Stakeholders will likely be keen to see how this change might influence the company's research and development strategies in the agri-business sector going forward.
As DCM Shriram navigates this leadership transition, the market will be watching closely to see how it maintains the momentum in its Bioseed Research Business, a crucial component of its agri-rural portfolio.
Historical Stock Returns for DCM Shriram Consolidated
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.37% | +4.61% | +11.61% | +28.13% | +22.23% | +288.60% |
















































